Literature DB >> 29022485

Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers.

Fermín Person1, Waldemar Wilczak1, Claudia Hube-Magg1, Christoph Burdelski2, Christina Möller-Koop1, Ronald Simon1, Mercedes Noriega1, Guido Sauter1, Stefan Steurer1, Susanne Burdak-Rothkamm1, Frank Jacobsen1.   

Abstract

Microtubules are multifunctional cytoskeletal proteins that are involved in crucial cellular roles including maintenance of cell shape, intracellular transport, meiosis, and mitosis. Class III beta-tubulin (βIII-tubulin, also known as TUBB3) is a microtubule protein, normally expressed in cells of neuronal origin. Its expression was also reported in various other tumor types, such as several types of lung cancer, ovarian cancer, and esophageal cancer. TUBB3 is of clinical relevance as overexpression has been linked to poor response to microtubule-targeting anti-cancer drugs such as taxanes. To systematically investigate the epidemiology of TUBB3 expression in normal and neoplastic tissues, we used tissue microarrays for analyzing the immunohistochemically detectable expression of TUBB3 in 3911 tissue samples from 100 different tumor categories and 76 different normal tissue types. At least 1 tumor with weak expression could be found in 93 of 100 (93%) different tumor types, and all these 93 entities also had at least 1 tumor with strong positivity. In normal tissues, a particularly strong expression was found in neurons of the brain, endothelium of blood vessels, fibroblasts, spermatogenic cells, stroma cells, endocrine cells, and acidophilic cells of the pituitary gland. In tumors, strong TUBB3 expression was most frequently found in various brain tumors (85%-100%), lung cancer (35%-80%), pancreatic adenocarcinoma (50%), renal cell carcinoma (15%-80%), and malignant melanoma (77%). In summary, these results identify a broad spectrum of cancers that can at least sporadically express TUBB3. Testing of TUBB3 in cancer types eligible for taxane-based therapies could be helpful to identify patients who might best benefit from this treatment.

Entities:  

Keywords:  expression; immunohistochemistry; multitumor tissue microarray; normal tissue; βIII-tubulin

Mesh:

Substances:

Year:  2017        PMID: 29022485     DOI: 10.1177/1010428317712166

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  16 in total

1.  Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

2.  RILPL2 regulates breast cancer proliferation, metastasis, and chemoresistance via the TUBB3/PTEN pathway.

Authors:  Guanglei Chen; Lisha Sun; Jianjun Han; Sufang Shi; Yuna Dai; Weiguang Liu
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

3.  Dissecting the role of the tubulin code in mitosis.

Authors:  Luísa T Ferreira; Ana C Figueiredo; Bernardo Orr; Danilo Lopes; Helder Maiato
Journal:  Methods Cell Biol       Date:  2018       Impact factor: 1.441

4.  Influence of Paclitaxel and Doxorubicin Therapy of ßIII-Tubulin, Carbonic Anhydrase IX, and Survivin in Chemically Induced Breast Cancer in Female Rat.

Authors:  Alena Pastornická; Silvia Rybárová; Slávka Drahošová; Jozef Mihalik; Andrea Kreheľová; Andriana Pavliuk-Karachevtseva; Ingrid Hodorová
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

5.  In situ characterization of stem cells-like biomarkers in meningiomas.

Authors:  Hanin Alamir; Mona Alomari; Abdulla Ahmed A Salwati; Mohamad Saka; Mohammed Bangash; Saleh Baeesa; Fahad Alghamdi; Angel Carracedo; Hans-Juergen Schulten; Adeel Chaudhary; Adel Abuzenadah; Deema Hussein
Journal:  Cancer Cell Int       Date:  2018-05-25       Impact factor: 5.722

Review 6.  Cutaneous melanoma dissemination is dependent on the malignant cell properties and factors of intercellular crosstalk in the cancer microenvironment (Review).

Authors:  Ondřej Kodet; Jan Kučera; Karolína Strnadová; Barbora Dvořánková; Jiří Štork; Lukáš Lacina; Karel Smetana
Journal:  Int J Oncol       Date:  2020-06-26       Impact factor: 5.650

Review 7.  Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells.

Authors:  Filip Borys; Ewa Joachimiak; Hanna Krawczyk; Hanna Fabczak
Journal:  Molecules       Date:  2020-08-14       Impact factor: 4.411

8.  Selectively high efficacy of eribulin against high-grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Authors:  Yutaka Kobayashi; Hiroko Kitahara; Mariko Hirai; Akira Tanaka; Rei Jokaji; Kazuhiko Kobayashi; George Bou-Gharios; Hiroyuki Nakamura; Shuichi Kawashiri
Journal:  Oncol Lett       Date:  2019-03-19       Impact factor: 2.967

9.  Neuroblastoma Formation Requires Unconventional CD4 T Cells and Arginase-1-Dependent Myeloid Cells.

Authors:  E Kaitlynn Allen; Jeremy Chase Crawford; Lee-Ann Van de Velde; Taylor L Wilson; Clifford S Guy; Marion Russier; Leonie Zeitler; Armita Bahrami; David Finkelstein; Stephane Pelletier; Stacey Schultz-Cherry; Paul G Thomas; Peter J Murray
Journal:  Cancer Res       Date:  2021-07-23       Impact factor: 12.701

10.  Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line.

Authors:  Kenichiro Yahiro; Yoshihiro Matsumoto; Jun-Ichi Fukushi; Ken-Ichi Kawaguchi; Makoto Endo; Nokitaka Setsu; Keiichiro IIda; Suguru Fukushima; Makoto Nakagawa; Atsushi Kimura; Yoshinao Oda; Yasuharu Nakashima
Journal:  Anal Cell Pathol (Amst)       Date:  2018-06-21       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.